EP4182452A4 - Methods for synthesizing non-anticoagulant heparan sulfate - Google Patents

Methods for synthesizing non-anticoagulant heparan sulfate Download PDF

Info

Publication number
EP4182452A4
EP4182452A4 EP21843488.4A EP21843488A EP4182452A4 EP 4182452 A4 EP4182452 A4 EP 4182452A4 EP 21843488 A EP21843488 A EP 21843488A EP 4182452 A4 EP4182452 A4 EP 4182452A4
Authority
EP
European Patent Office
Prior art keywords
methods
heparan sulfate
synthesizing non
anticoagulant heparan
anticoagulant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP21843488.4A
Other languages
German (de)
French (fr)
Other versions
EP4182452A1 (en
Inventor
Tarsis Ferreira GESTEIRA
Daniel H. LAJINESS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Optimvia LLC
Original Assignee
Optimvia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optimvia LLC filed Critical Optimvia LLC
Publication of EP4182452A1 publication Critical patent/EP4182452A1/en
Publication of EP4182452A4 publication Critical patent/EP4182452A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/13—Transferases (2.) transferring sulfur containing groups (2.8)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/10—Heparin; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y208/00—Transferases transferring sulfur-containing groups (2.8)
    • C12Y208/02—Sulfotransferases (2.8.2)
    • C12Y208/02023—[Heparan sulfate]-glucosamine 3-sulfotransferase 1 (2.8.2.23)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21843488.4A 2020-07-14 2021-07-14 Methods for synthesizing non-anticoagulant heparan sulfate Withdrawn EP4182452A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063051764P 2020-07-14 2020-07-14
PCT/US2021/041537 WO2022015794A1 (en) 2020-07-14 2021-07-14 Methods for synthesizing non-anticoagulant heparan sulfate

Publications (2)

Publication Number Publication Date
EP4182452A1 EP4182452A1 (en) 2023-05-24
EP4182452A4 true EP4182452A4 (en) 2024-07-31

Family

ID=79554994

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21843488.4A Withdrawn EP4182452A4 (en) 2020-07-14 2021-07-14 Methods for synthesizing non-anticoagulant heparan sulfate

Country Status (2)

Country Link
EP (1) EP4182452A4 (en)
WO (1) WO2022015794A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047755A2 (en) * 2004-10-27 2006-05-04 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (hit) syndrome
WO2009059284A2 (en) * 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3766167A (en) 1971-03-26 1973-10-16 Research Corp Orally active anticoagulant
DE2426586A1 (en) 1973-06-14 1975-01-09 Opocrin Srl PROCESS FOR THE PRODUCTION OF GLUCURONIL-GLUCOSAMINE-GLYCAN SULPHATES WITH ANTILIPAEMIC EFFECT
IT1083903B (en) 1977-08-09 1985-05-25 Lobo Srl OLIGO-ETEROPOLISACCARIDI WITH HEPARINOSIMIL ACTIVITIES, PROCEDURE FOR THEIR OBTAINING AND RELATED THERAPEUTIC COMPOSITIONS
FR2440376A1 (en) 1978-11-06 1980-05-30 Choay Sa MUCOPOLYSACCHARIDIC COMPOSITION HAVING REGULATORY COAGULATION ACTIVITY, MEDICAMENT CONTAINING SAME AND METHOD FOR OBTAINING SAME
US4500519A (en) 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US4692435A (en) 1978-11-06 1987-09-08 Choay, S.A. Mucopolysaccharide composition having a regulatory action on coagulation, medicament containing same and process of preparation
FR2478646A2 (en) 1980-03-20 1981-09-25 Choay Sa MUCOPOLYSACCHARIDIC COMPOSITION HAVING A COAGULATION REGULATING ACTIVITY, MEDICAMENT CONTAINING THE SAME, AND METHOD FOR OBTAINING THE SAME
CA1136620A (en) 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
GB2051103A (en) 1979-04-11 1981-01-14 Choay Sa Heparin fractions
US4826827A (en) 1979-10-05 1989-05-02 Choay S.A. Short chained oligosaccharides having biological properties, a process for making the same and the use thereof as drugs
IL61201A (en) 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
US4281108A (en) 1980-01-28 1981-07-28 Hepar Industries, Inc. Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained
FR2482611B1 (en) 1980-05-14 1986-03-07 Pharmindustrie NOVEL SULFATED POLYSACCHARIDES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
US4438261A (en) 1980-05-19 1984-03-20 Riker Laboratories, Inc. Anticoagulant substance
US4351938A (en) 1980-05-19 1982-09-28 Riker Laboratories, Inc. Anticoagulant substance
FR2503714B1 (en) 1981-04-10 1986-11-21 Choay Sa PROCESS FOR OBTAINING BIOLOGICALLY ACTIVE MUCOPOLYSACCHARIDES, OF HIGH PURITY, BY DEPOLYMERIZATION OF HEPARIN
FR2504928A1 (en) 1981-04-29 1982-11-05 Choay Sa SHORT CHAIN OLIGOSACCHARIDES HAVING BIOLOGICAL PROPERTIES, PREPARATION THEREOF AND APPLICATIONS THEREOF AS MEDICAMENTS
US4396762A (en) 1981-08-24 1983-08-02 Massachusetts Institute Of Technology Heparinase derived anticoagulants
ZA829463B (en) 1982-07-19 1983-10-26 Hepar Ind Inc Process for manufacturing low molecular weight heparins by depolymerization of normal heparin
US4533549A (en) 1983-01-04 1985-08-06 Lasker Sigmund E Antithrombotic agent
IT1195497B (en) 1983-03-08 1988-10-19 Opocrin Spa PROCEDURE FOR THE PREPARATION OF OLIGOSACCHARIDIC FRACTIONS EQUIPPED WITH PHARMACOLOGICAL PROPERTIES FOR CHEMICAL DEGRADATION OF HEPARIN
US4686388A (en) 1985-03-12 1987-08-11 Pitney Bowes Inc. Integrated circuit substrate bias selection circuit
DK196986D0 (en) 1986-04-30 1986-04-30 Novo Industri As PREPARATION OF POLYSACCHARIDES
DK196886D0 (en) 1986-04-30 1986-04-30 Novo Industri As PREPARATION OF POLYSACCHARIDES
US4833155A (en) 1986-11-25 1989-05-23 Syntex (U.S.A.) Inc. 3-(ω-(3,5,-di-t-butyl-4-hydroxyphenyl)-alkanoyl)pyrroles, and anti-inflammatory uses thereof
ES2003197A6 (en) 1987-01-05 1988-10-16 Rovi Lab Farmaceut Sa Process for the depolymerization of heparin for obtaining heparin with a low molecular weight and having an antithrombotic activity.
FR2614026B1 (en) 1987-04-16 1992-04-17 Sanofi Sa LOW MOLECULAR WEIGHT HEPARINS WITH REGULAR STRUCTURE, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS
IT1234508B (en) 1988-06-10 1992-05-19 Alfa Wassermann Spa HEPARIN DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION
US4981955A (en) 1988-06-28 1991-01-01 Lopez Lorenzo L Depolymerization method of heparin
IT1234826B (en) 1989-01-30 1992-05-29 Alfa Wassermann Spa HEPARIN DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION
EP0421508B1 (en) 1989-10-04 1993-12-15 Akzo Nobel N.V. Sulphated glycosaminoglycuronan with antithrombotic activity
USRE38743E1 (en) 1990-06-26 2005-06-14 Aventis Pharma S.A. Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events
FR2663639B1 (en) 1990-06-26 1994-03-18 Rhone Poulenc Sante LOW MOLECULAR WEIGHT POLYSACCHARIDE BLENDS PROCESS FOR PREPARATION AND USE.
US5821223A (en) 1990-09-14 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating cell growth with a novel broad spectrum human lung fibroblast-derived mitogen
SE9101155D0 (en) 1991-04-18 1991-04-18 Kabi Pharmacia Ab NOVEL HEPARIN DERIVATIVES
US5541095A (en) 1992-06-16 1996-07-30 University Of Massachusetts Medical Center Glycosaminoglycan specific sulfotransferases
US5668118A (en) 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
US5696100A (en) 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
US5296471A (en) 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
FR2704861B1 (en) 1993-05-07 1995-07-28 Sanofi Elf Purified heparin fractions, process for obtaining them and pharmaceutical compositions containing them.
JP3818676B2 (en) 1994-07-22 2006-09-06 生化学工業株式会社 Heparan sulfate 6-O-sulfotransferase
JP3672359B2 (en) 1995-07-24 2005-07-20 生化学工業株式会社 Heparan sulfate 2-O-sulfotransferase
DE69731386T2 (en) 1996-07-29 2006-02-16 Paringenix, Inc., Tucson PROCESS FOR TREATING ASTHMA WITH O-DESULFATED HEPARIN
US6861254B1 (en) 1997-10-24 2005-03-01 Massachusetts Institute Of Technology Heparan sulfate D-glucosaminyl 3-O-sulfotransferases, and uses therefor
US6255088B1 (en) 1999-05-11 2001-07-03 The Scripps Research Institute Enzymatic sulfation of biomolecules
DE10002005A1 (en) 2000-01-19 2001-08-09 Bosch Gmbh Robert Atomizing nozzle
US6489311B1 (en) 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
PT1319183E (en) 2000-09-12 2009-06-29 Massachusetts Inst Technology Methods and products related to low molecular weight heparin
EP1885865A4 (en) 2005-05-12 2010-12-22 Univ North Carolina ENZYMATIC SYNTHESIS OF SULFATE POLYSACCHARIDES
ATE453282T1 (en) 2005-07-05 2010-01-15 Huawei Tech Co Ltd AUTHENTICATION PROCEDURE FOR THE IP MULTIMEDIA SUBSYSTEM
EP2404939A3 (en) 2006-05-25 2012-03-21 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
US20090035787A1 (en) 2007-07-23 2009-02-05 The University Of North Carolina At Chapel Hill Enzymatic synthesis of sulfated polysaccharides without iduronic acid residues
KR101561860B1 (en) 2007-11-02 2015-10-20 모멘타 파머슈티컬스 인코포레이티드 Non-anticoagulant polysaccharide compositions
US11203772B2 (en) 2010-12-23 2021-12-21 The University Of North Carolina At Chapel Hill Chemoenzymatic synthesis of structurally homogeneous ultra-low molecular weight heparins
WO2013169355A1 (en) 2012-05-09 2013-11-14 Paringenix, Inc. Treatment of myelosuppression
ES2924830T3 (en) 2013-06-17 2022-10-11 Univ North Carolina Chapel Hill reversible heparin molecules
WO2016133910A1 (en) 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
HUE053923T2 (en) * 2015-12-28 2021-08-30 Ajinomoto Kk Method for producing heparan sulfate having anticoagulant activity
AU2020209822A1 (en) 2019-01-15 2021-09-09 Optimvia, Llc Engineered aryl sulfate-dependent enzymes
CN114616340A (en) 2019-07-09 2022-06-10 奥普蒂姆维亚有限公司 Method for synthesizing anticoagulant polysaccharide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047755A2 (en) * 2004-10-27 2006-05-04 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (hit) syndrome
WO2009059284A2 (en) * 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2022015794A1 *
ZACHARY SHRIVER ET AL: "Heparin and Heparan Sulfate: Analyzing Structure and Microheterogeneity", HANDBOOK OF EXPERIMENTAL PHARMACOLOGY, vol. 207, 2 December 2011 (2011-12-02), BERLIN, DE, pages 1 - 19, XP055657114, ISBN: 978-3-642-14540-7, DOI: 10.1007/978-3-642-23056-1_8 *

Also Published As

Publication number Publication date
EP4182452A1 (en) 2023-05-24
WO2022015794A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
CA3252857A1 (en) Novel methods
AU2022298331A1 (en) Methods
EP4118155A4 (en) Self-stratifying coatings
GB202306469D0 (en) Methods
GB202210325D0 (en) Methods
EP3971160A4 (en) Method for producing metal-organic structure
GB202205881D0 (en) Methods
EP4182452A4 (en) Methods for synthesizing non-anticoagulant heparan sulfate
EP3981795A4 (en) Method for producing polysaccharide ester
CA3252012A1 (en) Methods
GB202217332D0 (en) Methods
AU2022220400A9 (en) Process
HK40105505A (en) New process
CA3261656A1 (en) Nanoscale matrimeres
HK40107683A (en) Methods
HK40115938A (en) Process
AU2023902956A0 (en) Aluminosilicate nanoparticles
GB202410313D0 (en) Methods
GB202315216D0 (en) Methods
GB202314929D0 (en) Reduction process
GB202307381D0 (en) Methods
GB202305642D0 (en) Methods
GB202305510D0 (en) Methods
CA3252719A1 (en) Spatial-sequencing methods
GB202300597D0 (en) Methods

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C12N0009100000

Ipc: A61K0031277000

A4 Supplementary search report drawn up and despatched

Effective date: 20240703

RIC1 Information provided on ipc code assigned before grant

Ipc: C08L 5/10 20060101ALI20240627BHEP

Ipc: A61K 31/727 20060101ALI20240627BHEP

Ipc: C12P 19/26 20060101ALI20240627BHEP

Ipc: C12P 19/04 20060101ALI20240627BHEP

Ipc: C08B 37/00 20060101ALI20240627BHEP

Ipc: C12N 9/10 20060101ALI20240627BHEP

Ipc: A61K 31/277 20060101AFI20240627BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20250124